Vir Biotechnology (VIR) News Today → Nvidia needs this one obscure firm (From Porter & Company) (Ad) Free VIR Stock Alerts $11.21 -0.02 (-0.18%) (As of 04:15 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 11:48 AM | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Gap Down to $11.23Vir Biotechnology (NASDAQ:VIR) Shares Gap Down to $11.23June 9 at 6:42 AM | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Trading Down 8%June 8 at 5:50 AM | marketbeat.comRafferty Asset Management LLC Sells 126,347 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)Rafferty Asset Management LLC cut its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 24.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 398,970 shares of the company's stock after sellingJune 8 at 1:56 AM | americanbankingnews.comMorgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $15.00June 7 at 2:45 PM | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Down 8% Vir Biotechnology (NASDAQ:VIR) Trading Down 8%June 7 at 2:20 AM | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Vir Biotechnology (NASDAQ:VIR)June 6, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) PT Raised to $15.00 at Morgan StanleyMorgan Stanley boosted their target price on shares of Vir Biotechnology from $12.00 to $15.00 and gave the stock an "equal weight" rating in a research report on Thursday.June 6, 2024 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $19.00June 5, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Given New $19.00 Price Target at Needham & Company LLCNeedham & Company LLC boosted their price objective on Vir Biotechnology from $15.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday.June 5, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Vir Biotechnology (NASDAQ:VIR)HC Wainwright restated a "buy" rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Wednesday.June 5, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Gap Up to $10.58Vir Biotechnology (NASDAQ:VIR) Shares Gap Up to $10.58June 5, 2024 | businesswire.comTobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of TreatmentMay 29, 2024 | finance.yahoo.comVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 29, 2024 | businesswire.comVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 29, 2024 | msn.comResearchers discover vaccine originally created for HIV may also combat cancerMay 29, 2024 | markets.businessinsider.comVir Biotechnology Appoints Mark Eisner As EVP And Chief Medical OfficerMay 29, 2024 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from AnalystsVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommeMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology on Promising CHD and CHB Program ProspectsMay 24, 2024 | markets.businessinsider.comEvaluating Vir Biotechnology: Insights From 5 Financial AnalystsMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology on Promising HDV Program and Anticipated Trial ResultsMay 24, 2024 | marketbeat.comPanagora Asset Management Inc. Buys New Shares in Vir Biotechnology, Inc. (NASDAQ:VIR)Panagora Asset Management Inc. purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 94,516 shares of the company's stock, valued at approximately $951,000. Panagora AssetMay 23, 2024 | finance.yahoo.comVir Biotechnology to Host 2024 Annual Meeting of StockholdersMay 23, 2024 | businesswire.comVir Biotechnology to Host 2024 Annual Meeting of StockholdersMay 22, 2024 | finance.yahoo.comMultiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024May 21, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Stock Price Up 3.4%Vir Biotechnology (NASDAQ:VIR) Stock Price Up 3.4%May 21, 2024 | businesswire.comVir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024May 13, 2024 | prnewswire.comBrii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 StudiesMay 9, 2024 | marketbeat.comResearch Analysts Offer Predictions for Vir Biotechnology, Inc.'s FY2024 Earnings (NASDAQ:VIR)Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Research analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Vir Biotechnology in a research report issued on Tuesday, May 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will postMay 8, 2024 | finance.yahoo.comAnalysts Just Shipped A Stunning Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) EstimatesMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Anticipated Breakthroughs in Vir Biotechnology’s Clinical PipelineMay 7, 2024 | markets.businessinsider.comDeep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)May 7, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Tuesday.May 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology Amid Promising HDV and HBV Treatment MilestonesMay 3, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Announces Quarterly Earnings ResultsVir Biotechnology (NASDAQ:VIR - Get Free Report) posted its earnings results on Thursday. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.51. The company had revenue of $56.38 million during the quarter, compared to the consensus estimate of $11.71 million. Vir Biotechnology had a negative net margin of 713.69% and a negative return on equity of 34.92%. The firm's revenue for the quarter was down 10.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.06) earnings per share.May 3, 2024 | marketbeat.comVir Biotechnology's (VIR) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $15.00 price objective on shares of Vir Biotechnology in a report on Friday.May 3, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $12.00JPMorgan Chase & Co. increased their price objective on shares of Vir Biotechnology from $10.00 to $12.00 and gave the stock a "neutral" rating in a research report on Friday.May 3, 2024 | markets.businessinsider.comHold Rating on Vir Biotechnology Amid Financial Concerns and Clinical Trial UncertaintyMay 3, 2024 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Gap Up on Strong EarningsVir Biotechnology (NASDAQ:VIR) Shares Gap Up on Better-Than-Expected EarningsMay 3, 2024 | seekingalpha.comVir Biotechnology Provides Some Hope For Its Beleaguered ShareholdersMay 3, 2024 | finance.yahoo.comVir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 3, 2024 | finance.yahoo.comQ1 2024 Vir Biotechnology Inc Earnings CallMay 2, 2024 | investorplace.comVIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024May 2, 2024 | msn.comVir Biotechnology GAAP EPS of -$0.48 beats by $0.59, revenue of $56.38M beats by $44.67MMay 2, 2024 | businesswire.comVir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 1, 2024 | markets.businessinsider.comVir Biotechnology earnings preview: what Wall Street is expectingApril 30, 2024 | finance.yahoo.comVir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024April 28, 2024 | finance.yahoo.comWith 53% ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) boasts of strong institutional backingApril 26, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading 7.6% Higher Vir Biotechnology (NASDAQ:VIR) Trading Up 7.6%April 26, 2024 | msn.comSouthern policies help level up investment from East Asia Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address It's time to ween off Chinese lithium! (Ad)As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely Learn how this American company is leading the lithium-ion revolution VIR Media Mentions By Week VIR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIR News Sentiment▼0.590.76▲Average Medical News Sentiment VIR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIR Articles This Week▼144▲VIR Articles Average Week Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALLO News FATE News REPL News BLUE News KRYS News CRSP News IBRX News IMVT News SWTX News ACLX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIR) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored